Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-B15: Perioperative Enfortumab Vedotin Plus Pembrolizumab vs Neoadjuvant Chemotherapy in MIBC
NCT04700124Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2021
- Primary completion
- Oct 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs)
- Countries
- 29
01
Overview
A Phase 3 trial of enfortumab vedotin, pembrolizumab in muscle-invasive bladder cancer (MIBC), sponsored by Merck & Co.. Started Apr 2021; status: active, not recruiting.
02
Drugs
enfortumab vedotinpembrolizumab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT04700124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04700124.